Myasthenia gravis, thymectomy and serum thymic hormone activity

Area of Science:

• Endocrinology
• Immunology
• Neurology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• The thymus gland plays a role in immune system regulation and is implicated in MG pathogenesis.
• Serum thymic hormone activity may serve as a biomarker in MG.

Purpose of the Study:

• To measure serum thymic hormone activity in patients with myasthenia gravis.
• To investigate the effect of thymectomy on serum thymic hormone activity.
• To correlate changes in thymic hormone activity with clinical outcomes in MG patients.

Main Methods:

• Serum thymic hormone activity was quantified in 36 MG patients and 10 age-matched control subjects.
• Measurements were taken before and at various time points after thymectomy.
• Clinical status of patients was assessed and correlated with hormone levels.

Main Results:

• Elevated serum thymic hormone activity was observed in older MG patients compared to age-expected levels.
• One week post-thymectomy, 76% of patients showed no demonstrable thymic hormone activity.
• Long-term follow-up (≥10 months) revealed sustained low activity in 30% of patients.
• A significant correlation was found between sustained reduction in thymic hormone activity and clinical improvement.

Conclusions:

• Older patients with myasthenia gravis exhibit abnormal serum thymic hormone activity.
• Thymectomy effectively reduces serum thymic hormone activity in most MG patients.
• Sustained suppression of thymic hormone activity post-thymectomy is associated with clinical benefit in myasthenia gravis.